AI Generated
Jul 2, 2026, 10:29
Nisar Ahmed: The Evolution of Anticoagulation Therapy
Nisar Ahmed, Pharmacist at Zubair Pharmacy, shared a post on LinkedIn:
“70 years of warfarin vs the new generation.
Here’s why anticoagulation has changed forever.
Warfarin — blocks vitamin K clotting factors, needs constant INR monitoring, dozens of food and drug interactions.
Still irreplaceable for mechanical heart valves.
Apixaban (Eliquis) — directly inhibits Factor Xa, predictable, no monitoring, fewer interactions.
The landmark ARISTOTLE trial: 21% less stroke, 31% less major bleeding, 11% lower mortality vs warfarin in AF.
- Mechanical heart valve? Stick with warfarin – DOACs are contraindicated.
- Non-valvular AF or VTE? Apixaban is now the standard of care.
- Full breakdown in the infographic . “
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC
-
Aug 24, 2026, 14:09Stuart Andrew: NHS Blood and Transplant Strengthening the Blood Supply
-
Aug 24, 2026, 14:05Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement
-
Aug 24, 2026, 13:58Meera Chitlur: Transforming Care for Heavy Menstrual Bleeding at Children’s Hospital of Michigan
-
Aug 24, 2026, 13:49Heghine Khachatryan: Prepartum Acquired Hemophilia A and the Challenge of Maternal and Neonatal Bleeding
-
Aug 24, 2026, 13:44Neeraj Songara: Therapeutic Plasma Exchange in Severe Guillain–Barré Syndrome
-
Aug 24, 2026, 13:42Pall T. Onundarson: The Role of Measuring Treatment Effect in Optimizing DOAC and Warfarin Therapy